{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    42,
    43,
    44,
    45,
    47,
    48,
    49,
    50,
    60,
    63,
    73,
    74,
    75,
    76,
    77,
    78,
    111
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_4",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 60,
        "sourceText": "first dose",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_1",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 40,
        "sourceText": "Randomization visit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 20,
        "sourceText": "screening period",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "Informed \nconsent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_5",
        "definition": "Procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "Procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_7",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "Once daily"
      },
      {
        "id": "rep_daily_9",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_13",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P28D",
        "endOffset": "-P1D",
        "sourceText": "Day-28 to Day-1"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "-P28D",
        "endOffset": "-P1D",
        "sourceText": "Day -28 to Day -1"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "sourceText": "Screening \nPeriod"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "Screening period"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "Screening Period"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "Washout period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "observation \nperiod"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "7 days pre"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "sourceText": "24 hours before"
      },
      {
        "id": "rep_window_21",
        "type": "Continuous",
        "sourceText": "8 days before"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "P0D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "End of study period",
        "sourceText": "To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio)"
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "P0D",
        "minObservations": 1,
        "exitCondition": "End of study period",
        "sourceText": "ARR during the study period assessed by confirmed protocol-defined adjudicated relapses"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_3",
          "epoch_4",
          "epoch_6",
          "epoch_7"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "End of Study",
          "Screening"
        ],
        "sourceText": "[{'condition': 'If subject experiences AE requiring discontinuation', 'path': ['DEFINITIVE_DISCONTINUATION', 'EARLY_TERMINATION_VISIT', 'SAFETY_FOLLOW_UP']}, {'condition': 'Temporary discontinuation', 'path': ['TEMPORARY_DISCONTINUATION', 'RECHALLENGE', 'RESUME_TREATMENT']}, {'condition': 'Suspected MS relapse', 'path': ['UNSCHEDULED_ASSESSMENT_VISIT']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 1"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ae",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant \nMedications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 1"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Liver function test monitoring",
        "executionType": "Episode",
        "rationale": "Appendix 6 describes actions and follow-up assessments based on specific liver safety criteria and decision points."
      },
      {
        "activityId": "Week 3 Visit",
        "executionType": "Single",
        "rationale": "The amendment adds a specific one-time visit header at Week 3."
      },
      {
        "activityId": "Schedule of Activities (SoA)",
        "executionType": "Recurring",
        "rationale": "The SoA outlines assessments that are repeated across multiple study visits throughout the Phase 3 trial."
      },
      {
        "activityId": "CYP3A and CYP2C8 inhibitor monitoring",
        "executionType": "Window",
        "rationale": "The protocol requires continuous restriction and monitoring of prohibited medications (e.g., grapefruit juice) throughout the treatment period."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "eligibility_conditional",
        "text": "a Screening period can range from D-28 to D-1; Randomization visit can be performed only once IMPs are available at site. The interval between screening and randomization visits can range from 11 days (minimum) to 28 days (maximum). However, if required, the randomization visit can be performed earlier than 11 days upon IMP receipt at the site, assuming the participant is eligible for randomization. In case the screening MRI must be rescheduled (eg, technical issues) or repeated, an additional 1 week (7 days) is allowed.",
        "footnoteId": "fn_1",
        "structuredCondition": "duration.between(Screening, Randomization).min(P11D).max(P28D)",
        "appliesToActivityIds": [
          "Randomization"
        ],
        "sourceText": "a Screening period can range from D-28 to D-1; Randomization visit can be performed only once IMPs a"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b From D1 to EOS, unscheduled visits may be performed at any time by the Investigator (eg, for evaluation of an adverse event). Assessments may be done as needed to evaluate the participant in accordance with the Investigator's best judgment and in line with the study protocol. At a minimum, a physical examination should be performed, and, body temperature and vital signs should be measured.",
        "footnoteId": "fn_2",
        "structuredCondition": "frequency.unscheduled(as_needed)",
        "appliesToActivityIds": [
          "Physical examination",
          "Body temperature",
          "Vital signs"
        ],
        "sourceText": "b From D1 to EOS, unscheduled visits may be performed at any time by the Investigator (eg, for evalu"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c At the EOS, the participants who have completed the study and remain on IMP will be offered participation in a long-term safety study. Follow-up visit assessment only performed for those participants who are not willing to take part in the long-term safety study. For other situations where a follow-up visit is needed, please see Section 7.1 and the Study Manual.",
        "footnoteId": "fn_3",
        "structuredCondition": "eligibility.not_enrolled(Long-term safety study)",
        "appliesToActivityIds": [
          "Follow-up visit assessment"
        ],
        "sourceText": "c At the EOS, the participants who have completed the study and remain on IMP will be offered partic"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d These visits may be done as home health visits (where applicable) or onsite visits (preferable that tests are performed at the central laboratory). In any situations where this is not possible (to be documented in source documents), the tests for these visits may be performed at a local laboratory.",
        "footnoteId": "fn_4",
        "structuredCondition": "location.preference(Central Lab, Home Health, Local Lab)",
        "appliesToActivityIds": [
          "Laboratory tests"
        ],
        "sourceText": "d These visits may be done as home health visits (where applicable) or onsite visits (preferable tha"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "sequence",
        "text": "e If a participant prematurely permanently discontinues treatment with IMP, the participant will undergo a premature EOT visit as soon as possible. Participants will then be asked to continue with the study visits as scheduled, until global EOS visit is reached. During these visits, all study procedures/assessments will be performed except IMP administration and blood sampling for biomarkers (NfL, Chi3L1, and Ig levels). MRI scans for these participants will only be performed annually (using the next annual visit as the starting point).",
        "footnoteId": "fn_5",
        "structuredCondition": "if(treatment_discontinued).exclude(IMP administration, Biomarkers).frequency(MRI, P1Y)",
        "appliesToActivityIds": [
          "IMP administration",
          "Blood sampling for biomarkers",
          "MRI scans"
        ],
        "sourceText": "e If a participant prematurely permanently discontinues treatment with IMP, the participant will und"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "f Common EOS visit will be done when the prespecified number of events for 6-month CDW is expected to be reached. The timing and window of this visit will be communicated to sites.",
        "footnoteId": "fn_6",
        "sourceText": "f Common EOS visit will be done when the prespecified number of events for 6-month CDW is expected t"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_before",
        "text": "g Any disease-modifying therapy for MS taken at any time prior to signing the informed consent need to be reported in the CRF; other prior medications will be reported for the period of 6 months prior to signing the ICF.",
        "footnoteId": "fn_7",
        "structuredCondition": "history.report(DMT, all_prior); history.report(other, P6M).before(ICF)",
        "appliesToActivityIds": [
          "Prior medications"
        ],
        "sourceText": "g Any disease-modifying therapy for MS taken at any time prior to signing the informed consent need "
      },
      {
        "id": "fn_cond_8",
        "conditionType": "eligibility_conditional",
        "text": "h Additional safety assessments can be performed if required by local regulations; such testing may be performed locally. Additional visits may be added if required by local regulations.",
        "footnoteId": "fn_8",
        "sourceText": "h Additional safety assessments can be performed if required by local regulations; such testing may "
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_after",
        "text": "i Complete physical examination due at screening, baseline, yearly and EOS. Brief physical examination is sufficient for the rest of the visits (complete and brief physical examination will include neurological examination and collection of the following vital signs: arterial blood pressure, heart rate, and temperature).",
        "footnoteId": "fn_9",
        "structuredCondition": "if(Screening, Baseline, Yearly, EOS).type(Complete); else.type(Brief)",
        "appliesToActivityIds": [
          "Physical examination"
        ],
        "sourceText": "i Complete physical examination due at screening, baseline, yearly and EOS. Brief physical examinati"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "j To be performed at screening for all participants. To be repeated based on clinical judgment, borderline results, or clinical suspicion of TB infection. Screening tests for TB are described in Appendix 2 (Section 10.2).",
        "footnoteId": "fn_10",
        "sourceText": "j To be performed at screening for all participants. To be repeated based on clinical judgment, bord"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "sequence",
        "text": "k Hematology (platelet count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, reticulocytes, white blood cell count with differential: neutrophils, lymphocytes, monocytes, eosinophils, basophils). Biochemistry (blood urea nitrogen [BUN], creatinine, glucose, potassium, sodium, chloride, bicarbonate, calcium; liver function tests [AST, ALT, albumin, alkaline phosphatase, total and direct bilirubin, total protein; creatine phosphokinase], lipase at Screening Visit, then quarterly). Monthly visits (M1, M2, M4, M5) will include hematology and full liver panel only. Additional safety assessments can be performed if required by local regulations. Such testing shall be performed at local laboratories. Note: a one-time retest at screening may be performed if an abnormal laboratory test value is considered temporary. Additional visits may be added if required by local regulations.",
        "footnoteId": "fn_11",
        "structuredCondition": "if(M1, M2, M4, M5).subset(Hematology, Liver Panel); if(Screening).add(Lipase); else.frequency(Lipase, P3M)",
        "appliesToActivityIds": [
          "Hematology",
          "Biochemistry",
          "Lipase"
        ],
        "sourceText": "k Hematology (platelet count, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume,"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "l At intermediate timepoints (W2, W3, W5, W6, W7, W9, W10, W11, M7, M8, M10, and M11), only liver function tests will be collected (AST, ALT, albumin, alkaline phosphatase, total and direct bilirubin, total protein) and creatine phosphokinase; these can be performed at central laboratory (preferred, as on-site visits or home nursing as applicable for the site) or at local laboratory.",
        "footnoteId": "fn_12",
        "sourceText": "l At intermediate timepoints (W2, W3, W5, W6, W7, W9, W10, W11, M7, M8, M10, and M11), only liver fu"
      },
      {
        "id": "fn_cond_13",
        "conditionType": "timing_before",
        "text": "m Serum β-HCG pregnancy test at central laboratory at screening and urine pregnancy tests within 24 hours before the first dose of IMP and at scheduled times during study. Additional serum or urine pregnancy tests may be performed, as determined necessary by the Investigator or required by local regulation, to establish the absence of pregnancy at any time during the participant's participation in the study. Communication by phone of the result of a pregnancy test performed at home to the site is allowed. See also Appendix 4 (Section 10.4).",
        "footnoteId": "fn_13",
        "structuredCondition": "timing.before(the first dose of imp and at scheduled times during study. additional serum or urine pregnancy tests may be performed, as determined necessary by the investigator or required by local regulation, to establish the absence of pregnancy at any time during the participant's participation in the study. communication by phone of the result of a pregnancy test performed at home to the site is allowed. see also appendix 4 (section 10.4)., PT24M)",
        "appliesToActivityIds": [
          "Urine pregnancy test"
        ],
        "timingConstraint": "PT24H",
        "sourceText": "m Serum β-HCG pregnancy test at central laboratory at screening and urine pregnancy tests within 24 "
      },
      {
        "id": "fn_cond_14",
        "conditionType": "general",
        "text": "n Pregnancy tests will be performed monthly in all concerned EU countries (See Appendix 9, [Section 10.11.2]).",
        "footnoteId": "fn_14",
        "sourceText": "n Pregnancy tests will be performed monthly in all concerned EU countries (See Appendix 9, [Section "
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "o Only in female participants, if needed to establish menopausal status.",
        "footnoteId": "fn_15",
        "structuredCondition": "eligibility.sex(Female).and(status_unknown(Menopause))",
        "appliesToActivityIds": [
          "FSH/Hormone testing"
        ],
        "sourceText": "o Only in female participants, if needed to establish menopausal status."
      },
      {
        "id": "fn_cond_16",
        "conditionType": "sequence",
        "text": "p SDMT and CVLT-II will be performed in all participants. If for some reason, CVLT-II is not available at a given site due to reasons such as lack of translation, local certification, etc, then only the SDMT will be assessed for that participant.",
        "footnoteId": "fn_16",
        "sourceText": "p SDMT and CVLT-II will be performed in all participants. If for some reason, CVLT-II is not availab"
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_before",
        "text": "q A subset of sites that have 3T MRI capacity will perform additional sequences (eg, SWI). Further details will be defined in a separate central MRI manual. For systemic corticosteroids and adrenocorticotropic hormone, 1 month washout is required prior to the MRI scans. A visit window of ±21 days is acceptable for MRIs performed after D1. The screening MRI scan should be performed as close as possible before the start of IMP. As much as possible, the MRI scan should be performed during the screening period after it has been established that the participant meets all inclusion and no exclusion criteria.",
        "footnoteId": "fn_17",
        "structuredCondition": "timing.washout(Corticosteroids, P1M).before(MRI); timing.window(MRI, P21D).after(D1)",
        "appliesToActivityIds": [
          "MRI scans"
        ],
        "sourceText": "q A subset of sites that have 3T MRI capacity will perform additional sequences (eg, SWI). Further d"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "timing_before",
        "text": "r When available, clinical outcome assessments are to be completed by the participant prior to discussing their health status and prior to study treatment administration or other study-related procedures.",
        "footnoteId": "fn_18",
        "structuredCondition": "sequence.before(Health_status_discussion, IMP_administration, Procedures)",
        "appliesToActivityIds": [
          "Clinical outcome assessments"
        ],
        "sourceText": "r When available, clinical outcome assessments are to be completed by the participant prior to discu"
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "t Pharmacodynamics/biomarkers samples collected are not timed samples.",
        "footnoteId": "fn_20",
        "sourceText": "t Pharmacodynamics/biomarkers samples collected are not timed samples."
      },
      {
        "id": "fn_cond_20",
        "conditionType": "timing_after",
        "text": "u The DNA testing may be done, if locally applicable, at any time after signature of consent (in case it could not be done for some reason at Day 1).",
        "footnoteId": "fn_21",
        "sourceText": "u The DNA testing may be done, if locally applicable, at any time after signature of consent (in cas"
      },
      {
        "id": "fn_cond_21",
        "conditionType": "general",
        "text": "v This sample will be collected and stored for use if any unexpected safety issue occurs to ensure that a pre-dose baseline value is available for previously not assessed parameters (eg, serology) and for biomarkers research, if agreed.",
        "footnoteId": "fn_22",
        "sourceText": "v This sample will be collected and stored for use if any unexpected safety issue occurs to ensure t"
      },
      {
        "id": "fn_cond_22",
        "conditionType": "timing_before",
        "text": "w Samples for hematology and biochemistry tests on Day 1 (randomization) must be collected prior to administration of the first IMP dose.",
        "footnoteId": "fn_23",
        "structuredCondition": "timing.before(IMP_dose_1)",
        "appliesToActivityIds": [
          "Hematology",
          "Biochemistry"
        ],
        "sourceText": "w Samples for hematology and biochemistry tests on Day 1 (randomization) must be collected prior to "
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Adjudicated Relapse Rate",
        "endpointType": "Primary",
        "inputs": [
          "Relapse events",
          "Adjudication status",
          "Time on study"
        ],
        "timeWindow": {
          "reference": "Treatment period",
          "duration": "Study duration"
        },
        "algorithm": "Total number of adjudicated relapses / Total person-years of exposure",
        "successCriteria": "Statistically significant reduction in annualized rate compared to control (alpha = 0.05)",
        "sourceText": "Adjudicated relapse rate is the primary endpoint in this trial, being a standard endpoint used in pivotal RMS clinical studies"
      },
      {
        "id": "ep_2",
        "name": "Secondary: 6-month Confirmed Disability Worsening (CDW)",
        "endpointType": "Secondary",
        "inputs": [
          "EDSS score",
          "Relapse onset date",
          "Relapse resolution status",
          "Screening EDSS"
        ],
        "timeWindow": {
          "reference": "Initial onset of disability worsening",
          "duration": "P6M"
        },
        "algorithm": "Onset of EDSS increase maintained for >= 6 months. Confirmation EDSS must be > 30 days after a confirmed relapse and in the absence of ongoing relapse. Intervening EDSS scores must also maintain the minimum increase.",
        "successCriteria": "Maintenance of minimum EDSS increase from onset to 6-month confirmation visit",
        "sourceText": "Six-month confirmed disability worsening (CDW) is selected as the key secondary endpoint... for the purpose of confirmation, only EDSS score(s) measured more than 30 days after the onset of a confirme"
      },
      {
        "id": "ep_3",
        "name": "Safety: Treatment-Emergent Adverse Events (TEAE)",
        "endpointType": "Secondary",
        "inputs": [
          "Adverse Event (AE) onset date",
          "AE severity",
          "Study intervention start date"
        ],
        "timeWindow": {
          "reference": "Treatment period",
          "duration": "From first dose to end of treatment"
        },
        "algorithm": "AEs that developed, or worsened, or became serious during the treatment period",
        "successCriteria": "Descriptive analysis; no formal statistical significance testing",
        "sourceText": "TEAEs are defined as AEs that developed, or worsened, or became serious during the treatment period."
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Annualized Adjudicated Relapse Rate (ARR)",
        "variableType": "Custom",
        "sourceVariables": [
          "Confirmed protocol-defined adjudicated relapses",
          "Randomization date",
          "Last contact date",
          "EOS date"
        ],
        "derivationRule": "Total number of adjudicated relapses divided by observation duration (randomization to EOS or last contact date). Analyzed via negative binomial regression with log-transformed duration as offset.",
        "baselineDefinition": "Not applicable (rate over study period)",
        "analysisWindow": "Randomization to End-of-Study (EOS) or last contact date",
        "imputationRule": "No imputation for unobserved events after study discontinuation",
        "unit": "Relapses per year"
      },
      {
        "id": "dv_2",
        "name": "Time to onset of 6-month Confirmed Disability Worsening (CDW)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "EDSS score"
        ],
        "derivationRule": "Time from randomization to first EDSS increase (>=1.5 if baseline 0; >=1.0 if baseline 0.5-5.5; >=0.5 if baseline >5.5) confirmed at a scheduled visit at least 6 months later.",
        "baselineDefinition": "Baseline EDSS score",
        "baselineVisit": "Baseline",
        "analysisWindow": "Study duration until EOS",
        "imputationRule": "Kaplan-Meier estimates for censored data",
        "unit": "Days/Months"
      },
      {
        "id": "dv_3",
        "name": "Total number of new and/or enlarging T2-hyperintense lesions",
        "variableType": "Composite",
        "sourceVariables": [
          "T2-hyperintense lesions"
        ],
        "derivationRule": "Sum of the individual number of new and/or enlarging T2 lesions at all scheduled visits starting after baseline up to and including the EOS visit.",
        "baselineDefinition": "Baseline MRI scan",
        "baselineVisit": "Baseline",
        "analysisWindow": "Post-baseline visits through EOS",
        "imputationRule": "Not specified",
        "unit": "Count"
      },
      {
        "id": "dv_4",
        "name": "Total number of new Gd-enhancing T1-hyperintense lesions",
        "variableType": "Composite",
        "sourceVariables": [
          "Gd-enhancing T1-hyperintense lesions"
        ],
        "derivationRule": "Sum of the individual number of new Gd-enhancing T1-hyperintense lesions at all scheduled visits starting after baseline up to and including the EOS visit.",
        "baselineDefinition": "Baseline MRI scan",
        "baselineVisit": "Baseline",
        "analysisWindow": "Post-baseline visits through EOS",
        "imputationRule": "Not specified",
        "unit": "Count"
      },
      {
        "id": "dv_5",
        "name": "Time to Confirmed Disability Improvement (CDI)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "EDSS score"
        ],
        "derivationRule": "Time to a >=1.0 point decrease on the EDSS from the baseline EDSS score confirmed over at least 6 months.",
        "baselineDefinition": "Baseline EDSS score",
        "baselineVisit": "Baseline",
        "analysisWindow": "Study duration until EOS",
        "imputationRule": "Not specified",
        "unit": "Days/Months"
      },
      {
        "id": "dv_6",
        "name": "Percent change in brain volume loss",
        "variableType": "PercentChange",
        "sourceVariables": [
          "Brain volume"
        ],
        "derivationRule": "((EOS_value - Month6_value) / Month6_value) * 100",
        "baselineDefinition": "Month 6 MRI scan (Reference point)",
        "baselineVisit": "Month 6",
        "analysisWindow": "Month 6 to EOS",
        "imputationRule": "Not specified",
        "unit": "%"
      },
      {
        "id": "dv_7",
        "name": "Change in cognitive function (SDMT)",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Symbol Digit Modalities Test (SDMT) score"
        ],
        "derivationRule": "EOS_score - baseline_score",
        "baselineDefinition": "Last non-missing value prior to randomization",
        "baselineVisit": "Baseline",
        "analysisWindow": "Baseline to EOS",
        "imputationRule": "Not specified",
        "unit": "Score"
      },
      {
        "id": "dv_8",
        "name": "Change in MSQoL-54 score",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "MSQoL-54 questionnaire score"
        ],
        "derivationRule": "EOS_score - baseline_score",
        "baselineDefinition": "Last non-missing value prior to randomization",
        "baselineVisit": "Baseline",
        "analysisWindow": "Baseline to EOS",
        "imputationRule": "Not specified",
        "unit": "Score"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Year 1 (M12)",
        "From M15 to EOS",
        "For all participants",
        "Only for participants who completed treatment to EOS but do not enter LTS",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Year 1 (M12)",
          "trigger": "Progress to Year 1 (M12)"
        },
        {
          "fromState": "Year 1 (M12)",
          "toState": "From M15 to EOS",
          "trigger": "Progress to From M15 to EOS"
        },
        {
          "fromState": "From M15 to EOS",
          "toState": "For all participants",
          "trigger": "Progress to For all participants"
        },
        {
          "fromState": "For all participants",
          "toState": "Only for participants who completed treatment to EOS but do not enter LTS",
          "trigger": "Progress to Only for participants who completed treatment to EOS but do not enter LTS"
        },
        {
          "fromState": "Only for participants who completed treatment to EOS but do not enter LTS",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "epoch_1",
        "Year 1 (M12)": "epoch_3",
        "From M15 to EOS": "epoch_4",
        "For all participants": "epoch_6",
        "Only for participants who completed treatment to EOS but do not enter LTS": "epoch_7",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "SAR442168",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 60.0,
            "unit": "mg"
          },
          {
            "amount": 14.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "36 months",
        "sourceText": "ation on Day 1. Screening Period Treatment Period : approximately 18 to 36 months All patients continue in the study until Common Study End (EOS) 0 12 24 15 18 Months Teriflunomide 14 mg Oral N=450 SA"
      },
      {
        "id": "dosing_2",
        "treatmentName": "the SAR442168",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 30.0,
            "unit": "mg"
          },
          {
            "amount": 60.0,
            "unit": "mg"
          }
        ],
        "sourceText": "ug by the Investigators. Both participants completed the DRI15928 study and successfully rolled over to the LTS follow-up study. • One event of mild petechia in a female participant (at Week 8 in the "
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "SAR442168 (Tolebrutinib)",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "",
            "description": "Dose not specified in provided text snippet"
          }
        ],
        "durationDescription": "Not specified in text",
        "doseModifications": [
          "Liver function test monitoring guidance included for dose management"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Teriflunomide (Aubagio)",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "mg",
            "description": "Standard clinical dose"
          }
        ],
        "durationDescription": "Not specified in text"
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Placebo",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Not specified in text"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_8",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "(EDSS) score at screening (<4 versus ≥4) and geographic region (US versus non-US). Study intervention(s) Investigational medicinal product"
      },
      {
        "id": "visit_2",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "10.6 Appendix 6: Liver and other safety: actions and follow-up assessments Liver function test monitoring guidance"
      },
      {
        "id": "visit_4",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Treatment",
        "sourceText": "- increase of ≥1.5 points from the baseline Expanded Disability Status Scale (EDSS) score when the baseline score is 0, OR"
      },
      {
        "id": "visit_5",
        "visitName": "EOS",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Treatment",
        "sourceText": "Study (EOS) visit and number of new and/or enlarging T2-hyperintense lesions by visit over time •"
      },
      {
        "id": "visit_6",
        "visitName": "Month 6",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "epoch": "Treatment",
        "sourceText": "scans at the EOS compared to Month 6 • Change in cognitive function at the EOS compared to baseline"
      },
      {
        "id": "visit_9",
        "visitName": "Month 24",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "The proportion of participants with events at given time points (eg, Month 24) will be calculated using the Kaplan-Meier estimates. In this primary ITT analysis:"
      },
      {
        "id": "visit_12",
        "visitName": "EOT",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "pEOTe EOSf “Common"
      },
      {
        "id": "visit_13",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "Visit number V1 V2"
      },
      {
        "id": "visit_14",
        "visitName": "Visit 2",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "V2 V3"
      },
      {
        "id": "visit_15",
        "visitName": "Visit 3",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "V3 V4"
      },
      {
        "id": "visit_16",
        "visitName": "Visit 4",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "sourceText": "V4 V5"
      },
      {
        "id": "visit_17",
        "visitName": "Visit 5",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "V5 V6, V7"
      },
      {
        "id": "visit_18",
        "visitName": "Visit 6",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "sourceText": "V6, V7 V8"
      },
      {
        "id": "visit_19",
        "visitName": "Visit 7",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "V7 V8"
      },
      {
        "id": "visit_20",
        "visitName": "Visit 8",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 15,
        "sourceText": "V8 V9"
      },
      {
        "id": "visit_21",
        "visitName": "Visit 9",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "sourceText": "V9 V10"
      },
      {
        "id": "visit_22",
        "visitName": "Visit 10",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 17,
        "sourceText": "V10 V11, V12, V13, V14,"
      },
      {
        "id": "visit_23",
        "visitName": "Visit 11",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 18,
        "sourceText": "V11, V12, V13, V14, V15, V16,"
      },
      {
        "id": "visit_24",
        "visitName": "Visit 13",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "sourceText": "V13, V14, V15, V16, V17, V18…"
      },
      {
        "id": "visit_25",
        "visitName": "Visit 15",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 20,
        "sourceText": "V15, V16, V17, V18… V12,"
      },
      {
        "id": "visit_26",
        "visitName": "Visit 17",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 21,
        "sourceText": "V17, V18… V12, V14,"
      },
      {
        "id": "visit_27",
        "visitName": "Visit 12",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 22,
        "sourceText": "V12, V14, V16,"
      },
      {
        "id": "visit_28",
        "visitName": "Visit 14",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 23,
        "sourceText": "V14, V16, V18…"
      },
      {
        "id": "visit_29",
        "visitName": "Visit 16",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 24,
        "sourceText": "V16, V18… pEOTe"
      },
      {
        "id": "visit_30",
        "visitName": "Visit 18",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 25,
        "sourceText": "V18… pEOTe EOS"
      },
      {
        "id": "visit_7",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 26,
        "sourceText": "SAR442168 tablet daily. Randomization will be stratified by the Expanded Disability Status Scale (EDSS) score at screening (<4 versus ≥4) and geographic region (US versus non-US). Study intervention(s"
      },
      {
        "id": "visit_1",
        "visitName": "Week 3",
        "targetDay": 15,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 27,
        "targetWeek": 3,
        "epoch": "Treatment",
        "sourceText": "Week 3 added in the visit header and in footnote ‘l’. Update."
      },
      {
        "id": "visit_32",
        "visitName": "Week 4",
        "targetDay": 22,
        "windowBefore": 4,
        "windowAfter": 4,
        "isRequired": true,
        "visitNumber": 28,
        "targetWeek": 4,
        "sourceText": "within 4 days and 1 during the 60 mg SAR442168 treatment period [at Week 4, 107 U/L (normal range 6 to 34 U/L)]. The participant in the 60 mg group had slightly elevated ALT at screening (48 U/L) and "
      },
      {
        "id": "visit_31",
        "visitName": "Week 8",
        "targetDay": 50,
        "windowBefore": 4,
        "windowAfter": 4,
        "isRequired": true,
        "visitNumber": 29,
        "targetWeek": 8,
        "sourceText": "period [at Week 8, 105 U/L (normal range 6 to 34 U/L)] that returned to normal range within 4 days and 1 during the 60 mg SAR442168 treatment period [at Week 4, 107 U/L (normal range 6 to 34 U/L)]. Th"
      },
      {
        "id": "visit_33",
        "visitName": "Week 16",
        "targetDay": 106,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 30,
        "targetWeek": 16,
        "sourceText": "Week 16 in the SAR442168 30 mg group and 1 event on Day 1 in the SAR442168 60 mg group, with occult blood noted in urine) were reported during the treatment period in the SAR442168 Phase 2b trial. The"
      },
      {
        "id": "visit_3",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 31,
        "sourceText": "and follow-up assessments Liver function test monitoring guidance provided."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Region",
          "categories": [
            "North America",
            "Europe",
            "Asia",
            "Rest of World"
          ],
          "isBlocking": false,
          "sourceText": "the expanded disability status scale \n(edss) score at screening (<4 versus ≥4) and geographic region (us versus non-us)"
        },
        {
          "id": "strat_llm_1",
          "name": "Expanded Disability Status Scale (EDSS) score at screening",
          "categories": [
            "<4",
            "≥4"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Geographic region",
          "categories": [
            "US",
            "non-US"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Amended Clinical Trial Protocol 11  \n20-Dec-2023 \nSAR442168-EFC16034 - tolebrutinib \nVersion number: 1 \nProperty of the Sanofi group - strictly confidential \nPage 12 \nObjectives \nEndpoints \n• \nTo eval"
    }
  }
}